Advertisement

ESMO Latest

ESMO

Amivantamab-Lazertinib Combo for Resistant EGFR-positive NSCLC

Nov 25, 2020

At the European Society for Medical Oncology (ESMO) Virtual Congress 2020 , lead study investigator Prof. Byoung Chul Cho (Yonsei Cancer Centre, Yonsei University College of Medicine in Seoul, South Korea) presented the interim...

4-Year PACIFIC Data Hold Strong in NSCLC

Oct 27, 2020
Phase III ADAURA Trial: CNS Recurrences slashed for NSCLC

Oct 21, 2020
ESMO: Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC

Sep 24, 2020
ESMO: Bispecific antibodies targeting PD-1 and CTLA-4: new kids on the block(ade)

Sep 24, 2020

ESMO: PD-L1 density, a new predictive biomarker in NSCLC

Sep 24, 2020

PD-L1 expression is commonly used to predict response to immune checkpoint inhibitor therapy....

ESMO: Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence

Sep 24, 2020
ESMO: No advantage of post-operative radiotherapy in patients with stage IIIA N2 NSCLC

Sep 24, 2020
ESMO: Is adding an immune checkpoint inhibitor to targeted therapy the right approach?

Sep 24, 2020
ESMO: Is KRAS Finally ’Druggable’?

Sep 23, 2020

Advertisement